其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Salicylamide CAS Registry Number: 65-45-2 水杨酰胺

CAS Name: 2-Hydroxybenzamide
Trademarks: Salamid (Hamilton); Samid (Knoll); Cidal (CID); Salizell (Byk Gulden); Salymid (Biochemie); Urtosal (Lifepharma)
Percent Composition: C 61.31%, H 5.1...
Literature References: Prepn: A. Cahours, Ann. 48, 60 (1843); D. S. Hoffenberg, C. R. Hauser, J. Org. Chem. 20, 1496 (1955); J. B. Chattopadhyaya, A. V. Rama Rao, Tetrahedron 30, 2899 (1974). Toxicity data: Hart, J. Pharmacol. Exp. Ther. 89, 205 (1947). Clinical efficacy in headache: W. J. Murray, J. Clin. Pharmacol. J. New Drugs 7, 150 (1967). Pharmacokinetics: A. G. de Boer et al., Biopharm. Drug Dispos. 4, 321 (1983).

Difluprednate CAS Registry Number: 23674-86-4 二氟孕甾丁酯

CAS Name: (6a,11b)-21-(Acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione
Additional Names: 6a,9-difluoro-11b,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate ...
Literature References: Prepn: A. Ercoli, R. Gardi, ZA 6803686; A. Ercoli et al., US 3780177 (1968, 1973 both to Warner-Lambert). Anti-inflammatory properties: G. Di Pasquale et al., Steroids 16, 663, 679 (1970); R. Gardi et al., J. Med. Chem. 15, 556 (1972). Pharmacological study: J. Navarro et al., Arzneim.-Forsch. 28, 2302 (1978). Vasoconstrictive activity in man: A. Barbier et al., Therapie 33, 607 (1978). Bioavailability study: C. Lafille et al., Dermatologica 159, 277 (1979).

N-Methyl-N ¢ -nitro-N-nitrosoguanidine CAS Registry Number: 70-25-7 1-甲基-3-硝基-1-亚硝基胍

Additional Names: N-Methyl-N-nitroso-N'-nitroguanidine; MNNG
Percent Composition: C 16.33%, H 3.43%, N 47.61%, O 32.63%
Literature References: Prepn: A. F. McKay, G. F. Wright, J. Am. Chem. Soc. 69, 3028 (1947). Reviews of carcinogenicity and mutagenicity studies: IARC Monographs 4, 183-195 (1974); U. Sinha, B. B. Chattoo, J. Sci. Ind. Res. 3, 499-505 (1975).

Ropivacaine CAS Registry Number: 84057-95-4 罗哌卡因

CAS Name: (2S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide
Additional Names: (S)-(-)-1-propyl-2',6'-pipecoloxylidide; l-N-n-propylpipecolic acid-2,6-xylididePercent Composition: C 7...
Literature References: Prepn: A. F. Thuresson, C. Bovin, WO 8500599 (1985 to Apothekernes); H.-J. Federsel et al., Acta Chem. Scand. B41, 757 (1987). Physicochemical properties: G. R. Strichartz et al., Anesth. Analg. 71, 158 (1990). HPLC determn in human plasma: Z. Yu et al., J. Chromatogr. B 654, 221 (1994). In vitro metabolism: Y. Oda et al., Anesthesiology 82, 214 (1995). Clinical pharmacokinetics: D. J. Kopacz et al., ibid. 81, 1139 (1994). Toxicity study in sheep: A. C. Santos et al., ibid. 82, 734 (1995). Clinical evaluation in relief of surgical pain: I. Cederholm et al., Reg. Anesth. 19, 18 (1994); B. Johansson et al., Anesth. Analg. 78, 210 (1994); labor pain: R. Stienstra et al., ibid. 80, 285 (1995).

N-Methylformamide CAS Registry Number: 123-39-7 N-甲基甲酰胺

Additional Names: N-Monomethylformamide; NMF; MMFPercent Composition: C 40.67%, H 8.53%, N 23.71%, O 27.09%
Literature References: Prepn: A. Gautier, Ann. 151, 239 (1869); G. F. D'Alelio, E. E. Reid, J. Am. Chem. Soc. 59, 109 (1937); J. A. Marsella, G. P. Pez, J. Mol. Catal. 35, 65 (1986); J. J. Cappon et al., Recl. Trav. Chim. Pays-Bas 113, 318 (1994). Dielectric spectrum: J. Barthel et al., Chem. Phys. Lett. 167, 62 (1990). Toxicology: S. P. Langdon et al., Toxicology 34, 173 (1985). Review of metabolism, toxicity, and pharmacology: G. L. Kennedy, Jr., Crit. Rev. Toxicol. 17, 129-182 (1986). Review of antitumor activity and clinical evaluation: K. Clagett-Carr et al., J. Clin. Oncol. 6, 906-918 (1988).

Butedronic Acid CAS Registry Number: 51395-42-7 布替膦酸

CAS Name: (Diphosphonomethyl)butanedioic acid
Additional Names: (diphosphonomethyl)succinic acid; 2,3-dicarboxypropane-1,1-diphosphonic acid; DPD
Percent Composition: C 20.56%, H 3.45%, O 54...
Literature References: Prepn: A. Heins et al., DE 2217692 (1973 to Henkel); eidem, US 3923876 (1975 to Bayer A.G.); K. H. Worms, H. Blum, Z. Anorg. Allg. Chem. 457, 219 (1979); and physical-chemical properties: N. Vanlic-Razumenic et al., J. Serb. Chem. Soc. 51, 63 (1986). Clinical pharmacokinetics of 99mTc complex: C. Schümichen, H. Schmidt, Nuklearmedizin Suppl. 19, 930 (1982). Clinical evaluation of 99mTc complex as skeletal imaging agent: G. Godart et al., Clin. Nucl. Med. 11, 92 (1986).

Methallenestril CAS Registry Number: 517-18-0 美沙雌酸

CAS Name: b-Ethyl-6-methoxy-a,a-dimethyl-2-naphthalenepropanoic acid
Additional Names: b-(6-methoxy-2-naphthyl)-a,a-dimethylvaleric acid; 3-(6-methoxy-2-naphthyl)-2,2-dimethylpentanoic acid
...
Literature References: Prepn: A. Horeau, J. Jacques, Compt. Rend. 224, 862 (1947); J. Jacques, A. Horeau, Bull. Soc. Chim. Fr. 1948, 711; R. Gay, A. Horeau, ibid. 1955, 955.

Sulisobenzone CAS Registry Number: 4065-45-6 舒利苯酮

CAS Name: 5-Benzoyl-4-hydroxy-2-methoxybenzenesulfonic acid
Additional Names: 3-benzoyl-4-hydroxy-6-methoxybenzenesulfonic acid; 2-benzoyl-5-methoxy-1-phenol-4-sulfonic acid; 2-hydroxy-4-methox...
Literature References: Prepn: A. J. Cofrancesco, GB 1136525 (1968 to GAF). Activity: J. M. Knox et al., J. Invest. Dermatol. 34, 51 (1960).

Phenamidine CAS Registry Number: 101-62-2 4-(4-甲脒基苯氧基)苯甲脒二盐酸盐

CAS Name: 4,4'-Oxybisbenzenecarboximidamide
Additional Names: 4,4'-oxydibenzamidine; 4,4'-diamidinodiphenyl ether
Percent Composition: C 66.13%, H 5.55%, N 22.03%, O 6.29%
Literature References: Prepn: A. J. Ewins et al., GB 507565 (1939 to May Baker); J. N. Ashley et al., J. Chem. Soc. 1942, 103; of isethionate: G. Newbery, A. P. T. Easson, US 2410796 (1946 to May Baker). Trypanocidal activity: E. M. Lourie, W. Yorke, Ann. Trop. Med. Parasitol. 33, 289 (1939). Preliminary pharmacology: R. Wien, ibid. 37, 1 (1943). Use in treatment of Babesia infections in dogs: M. D. Ruff et al., Am. J. Vet. Res. 34, 641 (1973); R. Gothe et al., Kleintier-Praxis 32, 97 (1987). Early review of pharmacology, mode of action and clinical applications: E. M. Schoenbach, E. M. Greenspan, Medicine 27, 327-377 (1948).

Propamidine CAS Registry Number: 104-32-5 普罗帕脒

CAS Name: 4,4'-[1,3-Propanediylbis(oxy)]bisbenzenecarboximidamide
Additional Names: 4,4'-(trimethylenedioxy)dibenzamidine; 4,4'-diamidino-a,w-diphenoxypropane
Percent Composition: C 65.37%, ...
Literature References: Prepn: A. J. Ewins et al., GB 507565 (1939 to May Baker); J. N. Ashley et al., J. Chem. Soc. 1942, 103; of isethionate: G. Newbery, A. P. T. Easson: US 2394003 (1946 to May Baker). Trypanocidal activity: E. M. Lourie, W. Yorke, Ann. Trop. Med. Parasitol. 33, 289 (1939). Preliminary pharmacology: R. Wien, ibid. 37, 1 (1943). Determn in biological fluids: D. P. Jackson et al., J. Biol. Chem. 167, 377 (1947). Mode of action: M. J. Pine, Biochem. Pharmacol. 17, 75 (1968). Activity in fibrinolytic systems: J. D. Geratz, Thromb. Diath. Haemorrh. 29, 154 (1973). Clinical use in treatment of Acanthamoeba keratitis: D. L. Easty, Br. Med. J. 296, 228 (1988); J. J. Wiens, W. B. Jackson, Can. J. Ophthalmol. 23, 107 (1988). Early review of pharmacology, mode of action and clinical applications: E. B. Schoenbach, E. M. Greenspan, Medicine 27, 327-377 (1948).